Antibodies News and Research

RSS

Study points to one cause of higher rates of transplanted kidney rejection in blacks

A Johns Hopkins research team reports it may have an explanation for at least some of the higher organ rejection rates seen among black - as compared to white - kidney transplant recipients.

31 Aug 2008

Researchers discover key allergy gene

Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment (ZAUM) of the Technische Universitat Munchen, scientists at the Helmholtz Zentrum Munchen have pinpointed a major gene for allergic diseases. The gene was localized using cutting edge technologies for examining the whole human genome at the Helmholtz Zentrum Munchen.

24 Aug 2008

Researchers discover key details of how rheumatoid arthritis destroys bone

Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry. The findings are already guiding attempts to design new drugs to reverse RA-related bone loss and may also address more common forms of osteoporosis with a few adjustments.

24 Aug 2008

New discovery on how rheumatoid arthritis destroys bone

20 Aug 2008

Antibodies to 1918 flu pandemic may provide means to tackle bird flu threat

Scientists in the United States have discovered that elderly survivors of the original 1918 flu pandemic, still have immunity to the virus.

18 Aug 2008

NanoBio vaccine for hepatitis B shows promise

Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.

13 Aug 2008

New treatment in the pipeline for leukaemia and rheumatoid arthritis

Australian scientists believe they are well on the way to developing a new treatment for leukaemia and inflammatory diseases such as rheumatoid arthritis and asthma.

10 Aug 2008

Rituximab significantly reduces kidney injury in membranous nephropathy

The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN).

6 Aug 2008

Newly identified risk factor for cardiovascular disease may lead to new treatments

Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.

31 Jul 2008

New oral vaccine combats various versions of the plague

A University of Central Florida researcher may have found a defense against the Black Plague, a disease that wiped out a third of Europe's population in the Middle Ages and which government agencies perceive as a terrorist threat today.

31 Jul 2008

Promising new therapy for Alzheimer's

NewYork-Presbyterian Hospital/Weill Cornell Medical Center announced today the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous Immunoglobulin (IGIV) for Alzheimer's disease at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago.

From Baxter International Inc. 30 Jul 2008

Laboratory and mouse studies show targeted drug blocks the growth of breast cancer cells that spread to the brain

Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the growth of breast cancer cells that migrate to the brain.

29 Jul 2008

Roche starts acquisition process of ARIUS - fast tracks access to screening platform for antibody therapeutics

Roche and ARIUS Research Inc. have announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.

23 Jul 2008

Tobacco plant vaccine a cure for cancer?

Scientists in the U.S. say the tobacco plant could be used to "grow" key components of a cancer vaccine; they suggest that the same plant which is responsible for causing cancer may offer a way to treat the disease.

22 Jul 2008

Trial of treatment of inflammatory bowel disease begins at Tel Aviv Sourasky Medical Center

Anadis Ltd, a biopharmaceutical company focused on research, development and production of immune milk (colostrum)-derived polyclonal antibodies and other proteins to address major diseases, today announces the initiation of a clinical trial with top clinical scientists at Tel Aviv Sourasky Medical Center in Israel.

22 Jul 2008

First human tests of an injectable vaccine grown in genetically engineered plants

Plants could act as safe, speedy factories for growing antibodies for personalized treatments against a common form of cancer, according to new findings from the Stanford University School of Medicine. The findings came in the first human tests of an injectable vaccine grown in genetically engineered plants.

21 Jul 2008

HIV-I damages the immune system early than originally thought

New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days - not weeks - after transmission, as researchers had previously believed.

19 Jul 2008

Early exposure to tobacco smoke causes asthma and allergy

Babies exposed to cigarette smoke before birth or during the first months afterwards run a greater risk of developing asthma and allergy. This according to a doctoral thesis from the Swedish medical university Karolinska Institutet.

19 Jul 2008

NIAID will not conduct the PAVE 100 HIV vaccine study

After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.

17 Jul 2008

AFFiRiS GmbH alzheimer's vaccine progress

In the clinical phase I trial AFF001, AFFiRiS GmbH has now recruited the 24 Alzheimer patients planned for this trial. The trial aims to investigate the tolerability and safety of an innovative Alzheimer's vaccine (AFFITOPE AD01).

16 Jul 2008